Formosa and Eyenovia Partner for Clobetasol Propionate Development

Formosa Pharmaceuticals, situated in Taiwan, and Eyenovia have inked a non-binding conditions agreement to jointly develop Clobetasol Propionate Ophthalmic Suspension 0.05%, which is intended to provide temporary relief from dry eye symptoms. Due diligence will be conducted as part of the agreement, and efforts will be made to reach a final agreement that will divide development expenses and profits after commercialisation. This agreement extends the work between Eyenovia and Formosa, which included testing clobetasol propionate in the Optejet® and a meeting for consultation with the FDA regarding indications for dry eyes. A powerful steroid called clobetasol propionate, which the FDA licensed for use in the United States to lessen pain and inflammation following seven million eye procedures, may be used by millions of patients who have flare-ups.

The first product created with Formosa's exclusive APNT® nanoparticle formulation platform is Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%. This platform reduces the particle size of an active pharmaceutical ingredient with high uniformity and purity, facilitating penetration to pertinent compartments in the eye and improving bioavailability. The president and chief executive officer of Formosa Pharma, Eric Co, expressed excitement for the next phase of their collaboration with Eyenovia, noting that there is a great deal of potential for both businesses to realise APNT® formulations in cutting-edge delivery systems like Optejet®.